SGLT2 Inhibitors Safe for KTRs, Data Show
The safety profile of SGLT2 inhibitors in kidney transplant recipients with type 2 diabetes is similar to that of other patient populations, new research suggests.
Diabetes
Post-Kidney Transplant MACE Predicts Worse Survival
Kidney transplant recipients who had nonfatal MACE within the first year after transplant surgery, compared with those who did not, had a significantly lower 1-year survival rate (80.5% vs 97.4%).
ADA: Diabetes May Quadruple Risk for Long COVID
Authors say review findings are limited by heterogenous definitions of long COVID in published studies
ADA: Tirzepatide Improves Kidney Outcomes in T2DM With Increased CV Risk
Fewer renal complications seen with tirzepatide versus insulin glargine in adults with T2D and increased cardiovascular risk
Heart Failure Hospitalization Risk Compared With Empagliflozin vs Other Glucose-Lowering Tx
The EMPRISE study assessed the efficacy and safety of empagliflozin use in approximately 500,000 adults with type 2 diabetes.
Risk of New-Onset Type 2 Diabetes Up After Cancer Diagnosis
Adults with new onset type 2 diabetes in 2 years after diagnosis had increased risk of all-cause mortality
Fracture Risk in CKD Not Higher With SGLT2 Inhibitors
Patients with CKD are vulnerable to fractures due to CKD mineral bone disorder.
Diabetes in Kidney Transplant Recipients Ups Risk for Overall Graft Loss
The increased death risk associated with type 2 diabetes in kidney transplant recipients does not vary significantly by body mass index, according to investigators.
Metformin, Lifestyle Changes Cut Risk for T2DM, But Not CVD
No reduction seen in first occurrence of nonfatal MI, stroke, or CV death with either metformin or lifestyle intervention versus placebo
Early Glycemic Control May Cut CV Risk in Type 2 Diabetes
Greater glycemic variability is associated with increased risk for major adverse cardiovascular events
- Loading...
Loading...
Next post in Diabetes
Loading... 
Loading...